open access

Vol 13, No 6 (2018)
Evidence-based medicine — What's New?
Published online: 2019-03-04
Get Citation

Pharmacotherapy after ESC Congress 2018 in Munich - which questions have been answered?

Filip Pawliczak, Jarosław Damian Kasprzak
DOI: 10.5603/FC.2018.0126
·
Folia Cardiologica 2018;13(6):610-613.

open access

Vol 13, No 6 (2018)
Evidence-based medicine — What's New?
Published online: 2019-03-04

Abstract

During 5 hot-line sessions at ESC Congres 2018 in Munich several significant clinical trials' results were published. Authors selected top five trials answering the most important questions in pharmacotherapy of cardiovascular diseases.

Abstract

During 5 hot-line sessions at ESC Congres 2018 in Munich several significant clinical trials' results were published. Authors selected top five trials answering the most important questions in pharmacotherapy of cardiovascular diseases.

Get Citation

Keywords

pharmacotherapy; clinical trials; ESC Congress 2018; drugs; cardiovascular risk; mortality; safety; acetylsalicylic acid; infective endocarditis

About this article
Title

Pharmacotherapy after ESC Congress 2018 in Munich - which questions have been answered?

Journal

Folia Cardiologica

Issue

Vol 13, No 6 (2018)

Pages

610-613

Published online

2019-03-04

DOI

10.5603/FC.2018.0126

Bibliographic record

Folia Cardiologica 2018;13(6):610-613.

Keywords

pharmacotherapy
clinical trials
ESC Congress 2018
drugs
cardiovascular risk
mortality
safety
acetylsalicylic acid
infective endocarditis

Authors

Filip Pawliczak
Jarosław Damian Kasprzak

References (6)
  1. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018; 392(10152): 1036–1046.
  2. Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379(16): 1529–1539.
  3. Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements indiabetes mellitus. N Engl J Med. 2018; 379(16): 1540–1550.
  4. Maurer M, Schwartz J, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Eng J Med. 2018; 379(11): 1007–1016.
  5. Kojima S, Matsui K, Ogawa H, et al. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017; 69(1): 169–175.
  6. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019; 380(5): 415–424.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl